| ProductNum | picture | CAS No. | Name and description | Formula | Quick order | 
|---|---|---|---|---|---|
| CL2850 | 
                         | 
                    1673560-66-1 | 
                         PD-1-IN-17 98+%  | 
                    C13H22N6O7 | |
| CL2832A | 
                         | 
                    2113650-05-6 | 
                         BMS-1166 hydrochloride 98+%  | 
                    C36H34Cl2N2O7 | |
| CL2832 | 
                         | 
                    1818314-88-3 | 
                         BMS-1166 98+%  | 
                    C36H33ClN2O7 | |
| CLA1666 | 
                         | 
                    2329669-72-7 | 
                         Anti-Human PD-1xCTLA-4 Bispecific Antibody(Vudalimab;XmAb-20717,cytotoxic T-lymphocyte-associated protein 4, CD152;programmed cell death 1, PD1, PD-1, CD279) 95+%  | 
                    — | |
| CLA1320 | 
                         | 
                    1036730-42-3 | 
                         Pidilizumab (Anti-PDCD1 / PD-1 / CD279) 95+%  | 
                    — | |
| CLA1230 | 
                         | 
                    202833-08-7 | 
                         Atorolimumab 95+%  | 
                    — | |
| CLA1217 | 
                         | 
                    2411580-63-5 | 
                         Peresolimab (Anti-Human PD-1) 95+%  | 
                    — | |
| CLA1002 | 
                         | 
                    946414-94-4 | 
                         Nivolumab (anti-PD-1) (Synonyms:BMS-936558; ONO-4538; MDX-1106) 95+%  | 
                    — | |
| CLA1494 | 
                         | 
                    2394841-59-7 | 
                         Anti-Human PD-1xCTLA-4 Bispecific Antibody(Cadonilimab) 95+%  | 
                    — | |
| CLA1021 | 
                         | 
                    1380723-44-3 | 
                         Atezolizumab (anti-PD-L1) (Synonyms: MPDL3280A) 98+%  | 
                    — | |
| CLA1001 | 
                         | 
                    1374853-91-4 | 
                         Anti-Human PD-1 Monoclonal Antibody(Pembrolizumab biosimilar) mAb; MK-3475; Lambrolizumab 95+%  | 
                    — | |